Comparative Pharmacology
Head-to-head clinical analysis: EMLA versus POSIMIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMLA versus POSIMIR.
EMLA vs POSIMIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 mL (66 mg) of the 1.32% solution.
None Documented
None Documented
After topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Category C
Category C
Local Anesthetic
Local Anesthetic